Enosi Life Sciences

Expanding Visionary Autoimmune & Cancer Research and Combining Multiple Scientific Solutions to Achieve a Single Goal: Improving Lives


Anyone can invest


$25,000 minimum

About Enosi Life Sciences

Enosi Life Sciences is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and cancer. The company was founded by world-renowned scientists Professor Sir Marc Feldmann, who discovered anti-tumor necrosis factor (anti-TNF) therapy as an effective treatment for rheumatoid arthritis and other autoimmune diseases (Lasker Award, 2003 ); and Dr. H. Michael Shepard, whose research in humanized antibodies created the first monoclonal antibody therapy targeting cancer oncogene encoded-proteins ( Lasker award, 2019). Enosi Life Sciences consolidates Feldmann and Shepard’s expertise in cancer and autoimmune diseases with a unique combination of medical, scientific and management expertise to bring these two fields together for the purpose of creating new treatments for patients.

Next-Gen Breakthrough Biologics

More than 30% of patients treated with life-changing therapeutics do not respond, or relapse, even with continued treatment. Enosi Life Sciences’ founders are building upon their Lasker Award-winning research to address and conquer these issues.

Enosi’s founders are developing breakthrough biologics that will bring drugs with novel mechanisms of action, lower toxicity and improved patient outcomes than traditional therapeutics. This will be the next-generation of autoimmune, cancer and acute inflammation therapies that induce disease regression and prevent relapse, while dramatically-reducing patient side effects.


Dr. H. Michael Shepard

H. Michael Shepard, Ph.D.

CEO & Co-founder

  • Dr. H. Michael Shepard is a global, leading authority on cancer research and therapeutics.
  • Best known for his invention of “Herceptin”/Trastuzumab, which has remained one of the most profitable platforms for Roche (>$7B USD).
  • Dr. Shepard is a highly-experienced and respected leader with many successful ventures in this field – working at Genentech (sold to Roche – $46.8 B USD), Canji, Inc. (bought by Scheirng-Plough) and Halozyme (now valued at $2.6B USD).
  • Widely acknowledged biomarker pioneer and recognized worldwide, Dr. Shepard has received the 2019 Albert Lasker Award and the Warren Alpert Prize, among many other professional accolades.

Sir Marc Feldmann

Sir Marc Feldmann, M.D. Ph.D.

Director & Co-founder

  • Sir Marc Feldmann is a preeminent immunologist, and an Emeritus Professor at the University of Oxford.
  • With Sir Ravinder Maini, identified TNF as a target. Trials of Infliximab (Remicade) they led were successful, and prompted J&J’s $4.9B USD acquisition of Centocor.
  • Anti-TNF sales > $50B USD globally.
  • Professor Sir Marc Feldmann is a Fellow of the Royal Society , of Australian Academy and a Foreign Member of the US National Academy of Sciences; he was knighted in 2010 and received the Australian equivalent.
  • He has received many accolades including the Albert Lasker Award, the Crafoord Prize, the Canada Gairdner Award, the Paul Janssen Award, the Ernst Schering Award.

Dr. Shepard describes the invention of Herceptin

The 2019 Lasker~DeBakey Clinical Medical Research Award honors Michael Shepard, Dennis Slamon, and Axel Ullrich for  the invention of Herceptin, the first monoclonal antibody that blocks a cancer-causing protein, and for its development as a life-saving therapy for women with breast cancer.

Dr. H. Michael Shepard
Play Video
Sir Marc Feldmann
Play Video

Sir Marc Feldmann: Giants of Medicine Interview

Sir Marc Feldmann is interviewed by the Journal of Clinical Investigation regarding his research understanding autoimmune disease-specifically the treatment of rheumatoid arthritis (RA) – and the role of TNF and subsequent TNF Blockers.


At Enosi Life Sciences, we are committed to developing innovative treatments to address the global health challenges of autoimmune disease and cancer.